- Home
- ALLO vs SIBN Comparison
ALLO vs SIBN Comparison
Compare ALLO & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | SIBN |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 778.8M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALLO | SIBN |
|---|---|---|
| Price | $1.84 | $17.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | $8.35 | ★ $23.88 |
| AVG Volume (30 Days) | ★ 10.6M | 639.0K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.09 | ★ 41.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $67,301,000.00 |
| Revenue This Year | N/A | $16.95 |
| Revenue Next Year | $142,416.42 | $14.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.53 |
| 52 Week Low | $0.99 | $11.48 |
| 52 Week High | $4.46 | $21.89 |
Technical Indicators
Market Signals| Indicator | ALLO | SIBN |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 55.47 |
| Support Level | $1.56 | $16.42 |
| Resistance Level | $1.92 | $19.79 |
| Average True Range (ATR) | 0.12 | 0.74 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 16.85 | 42.86 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.